Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design

Future Oncology, Ahead of Print.

Source: Future Oncology - January 10, 2024 Category: Cancer & Oncology Authors: Robert L Ferris Hisham Mehanna Jonathan D Schoenfeld Makoto Tahara Sue S Yom Robert Haddad Andr é König Pauline Witzler Marcis Bajars Christophe Le Tourneau Source Type: research